Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Woodstock Corp

Woodstock Corp boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 52.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,115 shares of the biopharmaceutical company's stock after purchasing an additional 2,460 shares during the quarter. Woodstock Corp's holdings in Regeneron Pharmaceuticals were worth $4,513,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the period. Mediolanum International Funds Ltd lifted its holdings in shares of Regeneron Pharmaceuticals by 5.3% during the 4th quarter. Mediolanum International Funds Ltd now owns 4,449 shares of the biopharmaceutical company's stock worth $3,118,000 after acquiring an additional 224 shares during the period. Caprock Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 27.1% during the 4th quarter. Caprock Group LLC now owns 1,647 shares of the biopharmaceutical company's stock worth $1,173,000 after acquiring an additional 351 shares during the period. Factory Mutual Insurance Co. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $2,778,000. Finally, Concord Asset Management LLC VA lifted its holdings in shares of Regeneron Pharmaceuticals by 21.0% during the 4th quarter. Concord Asset Management LLC VA now owns 1,287 shares of the biopharmaceutical company's stock worth $917,000 after acquiring an additional 223 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of recent analyst reports. Royal Bank of Canada downgraded shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target for the company. in a report on Friday, May 30th. UBS Group lowered their price objective on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research report on Thursday. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Robert W. Baird lowered their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $844.48.

Regeneron Pharmaceuticals Stock Down 0.3%

Shares of REGN traded down $1.49 during mid-day trading on Thursday, hitting $483.44. 960,943 shares of the company traded hands, compared to its average volume of 851,110. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.79 and a 1-year high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $52.19 billion, a PE ratio of 12.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The business has a 50 day moving average of $575.25 and a 200 day moving average of $661.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter last year, the business earned $9.55 earnings per share. The business's revenue was down 3.7% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.